Gilead (GILD) Q3 2026 Earnings Call Transcript
Gilead (GILD) reported Q3 2026 earnings, highlighting strong performance. Trodelvy sales grew 42% YoY, reaching a $2B annual run rate. HIV sales increased 18% YoY, with Biktarvy achieving a 53% U.S. market share. The company raised 2026 revenue guidance by $1.6B. Gilead also discussed pipeline advancements in oncology and inflammation, including potential approvals and clinical trials. Total product sales, excluding Veklury, were $8.2B, up 16% YoY, driven by HIV, Trodelvy, and Livdelzi.
How this was made
The 30-second read
Why it matters
The disclosed guidance lift and sales growth provide fresh material for traders to reassess valuation.
Market read
First‑report earnings data for a large‑cap biotech; likely to move the stock and influence sector sentiment.
What to watch
Potential policy headwinds from CMS pricing decisions on Biktarvy could temper upside.
Background
Gilead's Q3 2026 earnings call highlighted strong performance across HIV, PrEP, oncology and liver disease pipelines, with new product launches and regulatory approvals.
Ticker impact
Q3 2026 earnings call disclosed a $2 B annual run‑rate for Trodelvy, raised 2026 revenue guidance by $1.6 B and reported strong HIV, PrEP and oncology sales.
potential upside as market prices in higher revenue guidance
The transcript provides first‑report numbers and a material guidance increase for a large‑cap biotech, which typically moves the stock in the same session.
Market effects
Positive momentum for biotech and HIV/oncology therapeutic segments.
U.S. biotech sector may see modest gains.
Limited to investors tracking large‑cap pharma earnings.
Counterpoint
If guidance is overly optimistic, the stock could face a pull‑back on subsequent detailed guidance.
Key entities
- companyGilead Sciences
US‑listed biotech firm reporting Q3 2026 results.
